Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$2.65 - $5.08 $869,804 - $1.67 Million
-328,228 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$4.73 - $7.9 $70,382 - $117,552
-14,880 Reduced 4.34%
328,228 $1.57 Million
Q3 2021

Nov 02, 2021

SELL
$5.16 - $7.98 $15,841 - $24,498
-3,070 Reduced 0.89%
343,108 $2.6 Million
Q2 2021

Aug 03, 2021

SELL
$6.45 - $9.09 $140,674 - $198,252
-21,810 Reduced 5.93%
346,178 $2.58 Million
Q1 2021

May 04, 2021

SELL
$7.25 - $13.82 $61,480 - $117,193
-8,480 Reduced 2.25%
367,988 $2.87 Million
Q4 2020

Feb 01, 2021

SELL
$6.87 - $10.48 $453,282 - $691,470
-65,980 Reduced 14.91%
376,468 $3.48 Million
Q3 2020

Nov 09, 2020

SELL
$5.06 - $7.23 $804,590 - $1.15 Million
-159,010 Reduced 26.44%
442,448 $3.05 Million
Q2 2020

Aug 07, 2020

SELL
$1.57 - $6.56 $113,222 - $473,080
-72,116 Reduced 10.71%
601,458 $3.95 Million
Q1 2020

May 04, 2020

BUY
$1.44 - $3.95 $271,330 - $744,274
188,424 Added 38.84%
673,574 $1.26 Million
Q4 2019

Feb 06, 2020

BUY
$1.17 - $2.33 $907 - $1,808
776 Added 0.16%
485,150 $912,000
Q4 2019

Feb 04, 2020

SELL
$1.17 - $2.33 $107,999 - $215,075
-92,307 Reduced 16.01%
484,374 $1.33 Million
Q3 2019

Nov 12, 2019

BUY
$1.4 - $2.84 $120,303 - $244,044
85,931 Added 17.51%
576,681 $819,000
Q2 2019

Aug 15, 2019

SELL
$2.75 - $4.89 $92,262 - $164,059
-33,550 Reduced 6.4%
490,750 $1.38 Million
Q1 2019

May 03, 2019

SELL
$4.11 - $5.88 $21,700 - $31,046
-5,280 Reduced 1.0%
524,300 $2.5 Million
Q4 2018

Feb 05, 2019

SELL
$3.65 - $10.69 $33,653 - $98,561
-9,220 Reduced 1.71%
529,580 $2.25 Million
Q3 2018

Nov 01, 2018

SELL
$8.92 - $17.83 $260,107 - $519,922
-29,160 Reduced 5.13%
538,800 $5.89 Million
Q2 2018

Aug 02, 2018

BUY
$12.83 - $17.41 $7.29 Million - $9.89 Million
567,960 New
567,960 $9.26 Million

Others Institutions Holding SURF

About Surface Oncology, Inc.


  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.